Sanofi CEO going to US, Bayer CEO going
This article was originally published in Scrip
French pharma giant Sanofi has confirmed that its CEO Christopher Viehbacher has moved to Boston, Massachusetts. He joins Elias Zerhouni (president of R&D), David-Alexandre Gros (chief strategy officer) and David Meeker (CEO of Sanofi's Genzyme unit), the other members of the 12-person executive committee who are based in the US.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.